Effects of neoadjuvant chemotherapy on hepatoblastoma: A morphologic and immunohistochemical study

American Journal of Surgical Pathology

Volumn 34, Issue 3, 2010, Pages 287-299

  Wang, Larry L ^a   Filippi, Renee Zon ^a   Zurakowski, David ^a   Archibald, Tonora ^a   Vargas, Sara O ^a   Voss, Stephan D ^a   Shamberger, Robert C ^a   Davies, Kimberly ^a   Kozakewich, Harry ^a   Perez Atayde, Antonio R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Beta catenin; Children; Cholangiocarcinoma; Cytokeratin; Hepatoblastoma; Hepatocellular carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; KERATIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BIOPSY; CANCER INVASION; CANCER STAGING; CELL NUCLEUS; CHEMISTRY; FEMALE; HEPATOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MORTALITY; NECROSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; BIOPSY; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; CHILD, PRESCHOOL; FEMALE; HEPATECTOMY; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN-MEIERS ESTIMATE; KERATINS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; NECROSIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77649226126     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181ce5f1e     Document Type: Article

References (25)

1. Cajaiba MM, Neves JI, Casarotti FF, et al. Hepatoblastomas and liver development: a study of cytokeratin immunoexpression in twenty-nine hepatoblastomas. Pediatr Dev Pathol. 2006;9: 196-202.
2. Chantelard J, Chiura E, Cleophax JP. Maturation of immature teratomas of the ovary. Apropos of a case and review of the literature. J Gynecol Obstet Biol Reprod (Paris). 1987;16: 861-867.
3. ClarkTG, Bradburn MJ, Love SB, et al. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89:232-238.
4. Coffin CM, Rulon J, Smith L, et al. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol. 1997;10: 1175-1187.
5. Dabbs DJ. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone; 2002.
6. Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem. 2004;52:1495-1501.
7. Gonzalez-Crussi F, Upton MP, Maurer HS. Hepatoblastoma. Attempt at characterization of histologic subtypes. Am J Surg Pathol. 1982;6:599-612.
8. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989;64:1082-1095.
9. Heifetz SA, French M, Correa M, et al. Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. Pediatr Pathol Lab Med. 1997;17:857-874.
10. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley; 2000.
11. Inukai T, Furuuchi K, Sugita K, et al. Nuclear accumulation of beta-catenin without an additional somatic mutation in coding region of the APC gene in hepatoblastoma from a familial adenomatous polyposis patient. Oncol Rep. 2004;11:121-126.
12. Lowichik A, Zhou H, Pysher TJ, et al. Therapy associated changes in childhood tumors. Adv Anat Pathol. 2000;7:341-359.
13. Montgomery E, Folpe AL. The diagnostic value of beta-catenin immunohistochemistry. Adv Anat Pathol. 2005;12:350-356.
14. Moskovic E, Jobling T, Fisher C, et al. Retroconversion of immature teratoma of the ovary: CT appearances. Clin Radiol. 1991;43:402-408.
15. Ortega JA, Rowland J, Monforte H, et al. Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome. J Pediatr Hematol Oncol. 2000;22:106-111.
16. Park WS, Oh RR, Park JY, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483-490.
17. Pontisso P, Barzon M, Basso G, et al. Cytokeratins patterns in childhood primary liver tumors. Int J Clin Lab Res. 1993;23:225-227.
18. Ranganathan S, Tan X, Monga SP. Beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol. 2005;8:435-447.
19. Roebuck DJ, Perilongo G. Hepatoblastoma: an oncological review. Pediatr Radiol. 2006;36:183-186.
20. Ruck P, Xiao JC, Kaiserling E. Small epithelial cells and the histogenesis of hepatoblastoma. Electron microscopic, immunoelectron microscopic, and immunohistochemical findings. Am J Pathol. 1996;148:321-329.
21. Saxena R, Leake JL, Shafford EA, et al. Chemotherapy effects on hepatoblastoma. A histological study. Am J Surg Pathol. 1993;17: 1266-1271.
22. Schnater JM, Kohler SE, Lamers WH, et al. Where do we stand with hepatoblastoma? A review. Cancer. 2003;98:668-678.
23. Smith LM, Anderson JR, Coffin CM. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol. 2002;38:398-404.
24. Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001;7:901-908.
25. Zuppan CW, Beckwith JB, Weeks DA, et al. The effect of preoperative therapy on the histologic features of Wilms' tumor. An analysis of cases from the Third National Wilms' Tumor Study. Cancer. 1991;68:385-394.